PFG Investments LLC Sells 9,819 Shares of Johnson & Johnson (NYSE:JNJ)

PFG Investments LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 95,566 shares of the company’s stock after selling 9,819 shares during the period. Johnson & Johnson comprises about 1.0% of PFG Investments LLC’s investment portfolio, making the stock its 12th biggest position. PFG Investments LLC’s holdings in Johnson & Johnson were worth $15,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Asio Capital LLC increased its stake in shares of Johnson & Johnson by 2.9% in the first quarter. Asio Capital LLC now owns 31,774 shares of the company’s stock valued at $5,026,000 after buying an additional 903 shares in the last quarter. Kathmere Capital Management LLC increased its position in Johnson & Johnson by 21.5% in the 1st quarter. Kathmere Capital Management LLC now owns 15,317 shares of the company’s stock valued at $2,423,000 after acquiring an additional 2,711 shares in the last quarter. Webster Bank N. A. raised its stake in shares of Johnson & Johnson by 0.6% in the first quarter. Webster Bank N. A. now owns 51,953 shares of the company’s stock worth $8,218,000 after acquiring an additional 285 shares during the last quarter. S.E.E.D. Planning Group LLC grew its stake in shares of Johnson & Johnson by 16.8% during the first quarter. S.E.E.D. Planning Group LLC now owns 33,344 shares of the company’s stock valued at $5,275,000 after purchasing an additional 4,797 shares during the last quarter. Finally, Norris Perne & French LLP MI raised its position in Johnson & Johnson by 4.1% in the 1st quarter. Norris Perne & French LLP MI now owns 107,328 shares of the company’s stock worth $16,978,000 after purchasing an additional 4,203 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $160.88 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market cap of $387.19 billion, a PE ratio of 10.03, a PEG ratio of 2.90 and a beta of 0.52. The firm’s fifty day moving average price is $163.41 and its two-hundred day moving average price is $155.10.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the business posted $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.08%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.